Bioavailability and Licensing - Clinical Research Informer

Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19.

The Pharma Data

JULY 12, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. For further information regarding our clinical trials, please visit [link] or [link]. About Molnupiravir.

Clinical Trials

Clinical Trials Clinical Trials Bioavailability Trials

Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal

The Pharma Data

JANUARY 5, 2021

Under the terms of the Ribometrix-Genentech collaboration, Genentech is paying Ribometrix $25 million up front, gaining exclusive rights to several predefined targets as well as an exclusive global license for the development and commercialization of compounds that come out of the collaboration.

RNA

RNA Protein Bioavailability DNA

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Ikena will back a pipeline that falls into two categories. Genentech will be accountable for further development and commercialization.

RNA

RNA Clinical Trials Clinical Trials Bioavailability

Lilly adds to pain pipeline with Asahi Kasei licensing deal

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.

Licensing

Licensing Licensing Bioavailability Antibody

Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev

Delveinsight

FEBRUARY 16, 2021

Maribavir is an orally bioavailable anti-CMV compound. The drug started its journey with GSK who evaluated its pre-clinical setting and out-licensed it to ViroPharma. Although cytomegalovirus infections are quite common and do not cause many symptoms, however, can be threatening in people with compromised immune systems.

Marketing

Marketing Protein Bioavailability Drugs

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

MARCH 8, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir. About Ridgeback Biotherapeutics.

Trials

Trials In-Vivo Genotoxicity RNA

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).

Bioavailability

Bioavailability In-Vivo In-Vitro Licensing

Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

The Pharma Data

AUGUST 16, 2021

Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. “Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability. 1-4 The U.S. ’s Chief Scientific Officer.

Dermatology

Dermatology Trials Bioavailability Medicine

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., Vigil’s $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. SciNeuro Pharmaceuticals.

Marketing

Marketing In-Vivo Protein In-Vitro

Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs

Drugs Protein Bioavailability Development

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor

The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec. ” About SOL-578.

Licensing

Licensing Licensing Bioavailability DNA

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

The Pharma Data

DECEMBER 1, 2020

The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is covered by more than 93 issued U.S. and international patents which provide protection out to 2040.

Trials

Trials Clinical Trials Clinical Trials Production

Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19

The Pharma Data

NOVEMBER 11, 2020

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About Selva Therapeutics.

Protein

Protein Bioavailability Development Licensing

Clinical Research Informer

Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19.

Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal

Trending Sources

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Lilly adds to pain pipeline with Asahi Kasei licensing deal

Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

Innovative Companies Diving into The Neuro Market Ahead of 2021

Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19

Stay Connected